Business
Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris
CHELMSFORD, Mass. & TOKYO, February 26, 2026--Asahi Kasei announced it has entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG.
About this update from Asahi Kasei Corporation
[{"type":"image","alt":"Progress of Asahi Kasei business portfolio transformation.","displaySize":"","headline":null,"caption":"Progress of Asahi Kasei business portfolio transformation.","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/0f3ed9265d9c0d27cc583c04687d37c3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tGyFNPV1ps7iOGVxN6qjpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0f3ed9265d9c0d27cc583c04687d37c3","width":480,"height":270}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4999,"height":683,"url":"https://media.zenfs.com/en/business-wire.com/ed644f5fa002b84da528cd8a29fe2c8f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OPqugcjPYh4KWhd.p3PBkg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ed644f5fa002b84da528cd8a29fe2c8f","width":960,"height":131},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/QJw16w1LA0C_sMyMZ.j7jw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ed644f5fa002b84da528cd8a29fe2c8f","width":1200,"height":164}}},{"type":"text","content":"Advancing Expansion in Severe Infectious Disease and Leveraging Existing Global Infrastructure to Drive Long-Term Growth","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"CHELMSFORD, Mass. & TOKYO, February 26, 2026--(BUSINESS WIRE)--Asahi Kasei announced it has entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG, a German-based biopharmaceutical company, for approximately €780 million*. This transaction expands Asahi Kasei’s specialty pharmaceutical platform further into severe infectious diseases and is expected to close in the first quarter of fiscal 2026, subject to customary conditions.","length":479,"tagName":"p"},{"type":"text","content":"Asahi Kasei expects the acquisition to contribute positively to operating income after amortization of goodwill and other intangible assets from fiscal 2028 onward.","length":164,"tagName":"p"},{"type":"text","content":"The acquisition advances Asahi Kasei’s strategy to build a focused, susta...